AbbVie | ABBV - Interest Expense On Debt

Stock Price
198.71
Daily Change
-2.24 -1.11%
Monthly
-4.09%
Yearly
6.80%
Q2 Forecast
194.46

AbbVie reported $740M in Interest Expense on Debt for its fiscal quarter ending in June of 2025.





Interest Expense On Debt Change Date
AbbVie USD 740M 40M Jun/2025
Abbott USD 68M 26M Mar/2026
ALKERMES USD 12.28M 7.63M Dec/2025
Amgen USD 653M 32M Dec/2025
AstraZeneca USD 484M 181M Dec/2025
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 2.78M 199K Dec/2025
Bristol-Myers Squibb USD 432M 48M Dec/2025
Coherus Biosciences USD 2.25M 76K Dec/2025
Eisai JPY 1.43B 12M Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Gilead Sciences USD 255M 1000K Dec/2025
GlaxoSmithKline GBP 188M 21M Dec/2025
Infinity Pharmaceuticals USD 45K 0 Jun/2023
J&J USD 43M 25M Mar/2026
Medtronic USD 181M 0 Dec/2025
Merck USD 412M 85M Dec/2025
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Novartis USD 304M 23M Dec/2025
Pacira USD 3.89M 387K Dec/2025
Perrigo USD 10.08B 10.04B Sep/2025
Pfizer USD 711M 59M Dec/2025
Regeneron Pharmaceuticals USD 12.2M 7.1M Dec/2025
Roche Holding CHF 304M 7.5M Jun/2025
Sanofi EUR 178M 203M Mar/2026
UCB EUR 49M 29M Dec/2025
Ultragenyx Pharmaceutical USD 19M 4.85M Dec/2025
United Therapeutics USD 3.1M 100K Dec/2025
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025
Zoetis USD 57M 1000K Dec/2025